SCHEMBL4501649

SCHEMBL4501649

CCCCCN(CC)C(=O)CC

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 4/20 0.52
CA1 P00915 4/20 0.52
CA9 Q16790 4/20 0.52
MGLL Q99685 1/20 0.48
LMNA P02545 1/20 0.44
CA2 P00918 2/20 0.43
MMP1 P03956 1/20 0.42
MMP2 P08253 1/20 0.42
MMP3 P08254 1/20 0.42
MMP8 P22894 1/20 0.42
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C19 P33261 1/20 0.41
ZDHHC20 Q5W0Z9 2/20 0.40
ZDHHC2 Q9UIJ5 1/20 0.40
GAA P10253 1/20 0.39
HPGD P15428 1/20 0.39
S1PR2 O95136 1/20 0.38
S1PR1 P21453 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14259804 0.98 MGLL (0.52) CA12CA1CA9MGLLLMNA
SCHEMBL10795632 0.98 MGLL (0.52) CA12CA1CA9MGLLLMNA
SCHEMBL27497163 0.98 MGLL (0.52) CA12CA1CA9MGLLLMNA
SCHEMBL13850464 0.93 CA12 (0.59) CA12CA1CA9MGLLLMNA
SCHEMBL4148813 0.91 CA12 (0.48) CA12CA1CA9MGLLCA2
SCHEMBL4148175 0.88 CA12 (0.50) CA12CA1CA9MGLLCA2
SCHEMBL4155059 0.88 CA12 (0.50) CA12CA1CA9MGLLCA2
SCHEMBL4148017 0.88 CA12 (0.50) CA12CA1CA9MGLLCA2
SCHEMBL4155142 0.88 CA12 (0.50) CA12CA1CA9MGLLCA2
SCHEMBL4155093 0.88 CA12 (0.50) CA12CA1CA9MGLLCA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022262516-A1 LINKER AND CONJUGATE THEREFOR 北京海步医药科技有限公司 2022-12-22 WO disclosed
EP-1611104-B1 TETRAHYDROISOQUINOLYL ACETAMIDE DERIVATIVES FOR USE AS OREXIN RECEPTOR ANTAGONISTS ACTELION PHARMACEUTICALS LTD (CH) 2009-07-01 EP disclosed
US-20060178515-A1 Tetrahydroisoquinolyl acetamide derivatives for use as orexin receptor antagonists ACTELION PHARMACEUTICALS, LTD. (CH) 2006-08-10 US disclosed
EP-1611104-A1 TETRAHYDROISOQUINOLYL ACETAMIDE DERIVATIVES FOR USE AS OREXIN RECEPTOR ANTAGONISTS Actelion Pharmaceuticals Ltd. (CH) 2006-01-04 EP disclosed
WO-2004085403-A1 TETRAHYDROISOQUINOLYL ACETAMIDE DERIVATIVES FOR USE AS OREXIN RECEPTOR ANTAGONISTS ACTELION PHARMACEUTICALS LTD (CH) 2004-10-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060178515-A1 Tetrahydroisoquinolyl acetamide derivatives for use as orexin receptor antagonists HCRTR2, HCRTR1, OXTR CA12 1934/4885CA1 466/4885CA9 1650/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.